Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Systemic and local interferon-gamma production following Mycobacterium ulcerans infection.

Schipper HS, Rutgers B, Huitema MG, Etuaful SN, Westenbrink BD, Limburg PC, Timens W, van der Werf TS.

Clin Exp Immunol. 2007 Dec;150(3):451-9. Epub 2007 Sep 27.

2.

Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease.

Prévot G, Bourreau E, Pascalis H, Pradinaud R, Tanghe A, Huygen K, Launois P.

Infect Immun. 2004 Feb;72(2):958-65.

3.

Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis.

Phillips R, Horsfield C, Kuijper S, Sarfo SF, Obeng-Baah J, Etuaful S, Nyamekye B, Awuah P, Nyarko KM, Osei-Sarpong F, Lucas S, Kolk AH, Wansbrough-Jones M.

Clin Vaccine Immunol. 2006 Feb;13(2):253-7.

4.

Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana.

Westenbrink BD, Stienstra Y, Huitema MG, Thompson WA, Klutse EO, Ampadu EO, Boezen HM, Limburg PC, van der Werf TS.

Clin Diagn Lab Immunol. 2005 Jan;12(1):125-9.

5.

Systemic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans.

Yeboah-Manu D, Peduzzi E, Mensah-Quainoo E, Asante-Poku A, Ofori-Adjei D, Pluschke G, Daubenberger CA.

J Leukoc Biol. 2006 Jun;79(6):1150-6. Epub 2006 Mar 10.

PMID:
16531561
6.

Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans.

Sarfo FS, Phillips RO, Ampadu E, Sarpong F, Adentwe E, Wansbrough-Jones M.

Clin Vaccine Immunol. 2009 Jan;16(1):61-5. doi: 10.1128/CVI.00235-08. Epub 2008 Nov 12.

7.

Multiple Mycobacterium antigens induce interferon-gamma production from sarcoidosis peripheral blood mononuclear cells.

Carlisle J, Evans W, Hajizadeh R, Nadaf M, Shepherd B, Ott RD, Richter K, Drake W.

Clin Exp Immunol. 2007 Dec;150(3):460-8. Epub 2007 Oct 9.

8.

Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.

Fraga AG, Martins TG, Torrado E, Huygen K, Portaels F, Silva MT, Castro AG, Pedrosa J.

PLoS One. 2012;7(3):e33406. doi: 10.1371/journal.pone.0033406. Epub 2012 Mar 8.

9.

Immune response to infection with Mycobacterium ulcerans.

Gooding TM, Johnson PD, Campbell DE, Hayman JA, Hartland EL, Kemp AS, Robins-Browne RM.

Infect Immun. 2001 Mar;69(3):1704-7.

10.

Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer.

Bolz M, Bénard A, Dreyer AM, Kerber S, Vettiger A, Oehlmann W, Singh M, Duthie MS, Pluschke G.

PLoS Negl Trop Dis. 2016 Feb 5;10(2):e0004431. doi: 10.1371/journal.pntd.0004431. eCollection 2016 Feb.

11.

Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease.

Phillips R, Sarfo FS, Guenin-Macé L, Decalf J, Wansbrough-Jones M, Albert ML, Demangel C.

J Infect Dis. 2009 Dec 1;200(11):1675-84. doi: 10.1086/646615.

PMID:
19863437
12.

In Th2-biased lymphatic filarial patients, responses to purified protein derivative of Mycobacterium tuberculosis remain Th1.

Sartono E, Kruize YC, Kurniawan A, Maizels RM, Yazdanbakhsh M.

Eur J Immunol. 1996 Feb;26(2):501-4.

PMID:
8617323
13.

Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts.

Gooding TM, Johnson PD, Smith M, Kemp AS, Robins-Browne RM.

Infect Immun. 2002 Oct;70(10):5562-7.

14.

Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions.

Schütte D, Umboock A, Pluschke G.

Br J Dermatol. 2009 Feb;160(2):273-83. doi: 10.1111/j.1365-2133.2008.08879.x. Epub 2008 Oct 22.

PMID:
19016694
15.

Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Fraga AG, Cruz A, Martins TG, Torrado E, Saraiva M, Pereira DR, Meyers WM, Portaels F, Silva MT, Castro AG, Pedrosa J.

Infect Immun. 2011 Jan;79(1):421-30. doi: 10.1128/IAI.00820-10. Epub 2010 Oct 25.

16.

Interferon-γ Is a Crucial Activator of Early Host Immune Defense against Mycobacterium ulcerans Infection in Mice.

Bieri R, Bolz M, Ruf MT, Pluschke G.

PLoS Negl Trop Dis. 2016 Feb 10;10(2):e0004450. doi: 10.1371/journal.pntd.0004450. eCollection 2016 Feb.

17.

The local immune response in ulcerative lesions of Buruli disease.

Kiszewski AE, Becerril E, Aguilar LD, Kader IT, Myers W, Portaels F, Hernàndez Pando R.

Clin Exp Immunol. 2006 Mar;143(3):445-51.

20.

Modulation of T-cell responses to a recall antigen in human T-cell leukemia virus type 1-infected individuals.

Suzuki M, Dezzutti CS, Okayama A, Tachibana N, Tsubouchi H, Mueller N, Lal RB.

Clin Diagn Lab Immunol. 1999 Sep;6(5):713-7.

Supplemental Content

Support Center